SHG:688105 - Nanjing Vazyme Biotech Co Ltd

Nanjing Vazyme Biotech Co Ltd
Sector: Health Care, Industry: Biotechnology

Add to Watchlist

•  Default
• New Watchlist

   

Yahoo Finance

• Summary
• Financials
• Dividend
• Prices
• Posts
• User
• Alerts

Balance Sheet Cash Flow Income Statement Key Ratios Personalized Adjust Display Metrics

Show %	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	Graph
Insider Holdings (%)	[friend]	[friend]	[friend]	[friend]	[friend]	-	-	-	-	72.82% -	72.82% 0%	70.81% -2.8%	70.81% 0%	70.81% 0%	74.56% 5.3%
Net Margin	[friend]	[friend]	[friend]	[friend]	[friend]	19.49% -68.6%	34.2% 75.4%	22.08% -35.4%	44.23% 100.3%	28.33% -35.9%	19.82% -30.1%	-12.3% -	-16.75% -	-11.33% -	1.58% -
Gross Margin	[friend]	[friend]	[friend]	[friend]	[friend]	76.08% -17.7%	86.52% 13.7%	69.04% -20.2%	74.77% 8.3%	73.16% -2.1%	69.78% -4.6%	61.68% -11.6%	68.67% 11.3%	76.35% 11.2%	68.33% -10.5%
Operating Margin	[friend]	[friend]	[friend]	[friend]	[friend]	24.11% -66.6%	41.16% 70.7%	25.28% -38.6%	53.17% 110.3%	32.47% -38.9%	22.24% -31.5%	28.22% 26.9%	-11.15% -	-21.06% -	-2.14% -
Total Revenue	[friend]	[friend]	[friend]	[friend]	[friend]	283.92M -47.6%	463.07M 63.1%	580M 25.3%	975.34M 68.2%	644.38M -33.9%	685.3M 6.4%	1.26B 84.4%	302.19M -76.1%	268.84M -11.0%	298.26M 10.9%
Total Assets	[friend]	[friend]	[friend]	[friend]	[friend]	2.14B 3.4%	2.29B 7.2%	4.61B 101.2%	5.46B 18.5%	5.47B 0.2%	5.89B 7.6%	6.01B 2.0%	6.32B 5.2%	5.76B -8.9%	5.71B -0.8%
Total Liabilities	[friend]	[friend]	[friend]	[friend]	[friend]	407.23M 3.6%	401.48M -1.4%	479.83M 19.5%	898.45M 87.2%	844.05M -6.1%	1.12B 32.5%	1.39B 24.5%	1.77B 26.9%	1.74B -1.6%	1.69B -2.6%
Total Equity	[friend]	[friend]	[friend]	[friend]	[friend]	1.73B 3.4%	1.89B 9.3%	4.13B 118.6%	4.56B 10.5%	4.62B 1.4%	4.76B 3.0%	4.61B -3.2%	4.55B -1.3%	4.02B -11.7%	4.02B 0.0%
Operating CashFlow	[friend]	[friend]	[friend]	[friend]	[friend]	308.2M -	-	-	-	131.1M -	-	-	-	44.77M -	-
Beginning Cash Position	[friend]	[friend]	[friend]	[friend]	[friend]	195.17M -11.9%	250.12M 28.2%	41.35M -83.5%	1.48B 3473.5%	844.29M -42.9%	809.38M -4.1%	953.48M 17.8%	1.34B 41.0%	1.4B 4.4%	1.77B 25.9%
End Cash Position	[friend]	[friend]	[friend]	[friend]	[friend]	250.12M 28.2%	41.35M -83.5%	1.48B 3473.5%	844.29M -42.9%	809.38M -4.1%	953.48M 17.8%	1.34B 41.0%	1.4B 4.4%	1.77B 25.9%	827.36M -53.2%
Free Cash Flow	[friend]	[friend]	[friend]	[friend]	[friend]	-11.04M -	-80.54M -	271.93M -	-303.24M -	-179.64M -	-155.86M -	411.04M -	-203.54M -	74.59M -	-130.26M -
Net Income (Cont Operations)	[friend]	[friend]	[friend]	[friend]	[friend]	391.86M -	-	-	-	613.94M -	-	-	-	-81.99M -	-
Diluted Net Income	[friend]	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-	-	-	-	-	-
Diluted EPS	[friend]	[friend]	[friend]	[friend]	[friend]	0.16 -82.8%	0.44 175.0%	0.34 -22.7%	1.08 217.6%	0.45 -58.3%	0.34 -24.4%	-0.38 -	-0.13 -	-0.07 -	0.01 -
Return On Equity (%)	[friend]	[friend]	[friend]	[friend]	[friend]	3.26% -85.5%	8.76% 168.9%	4.26% -51.4%	9.93% 133.2%	3.98% -60.0%	2.89% -27.2%	-3.32% -	-1.11% -	-0.71% -	0.12% -
Return On Assets (%)	[friend]	[friend]	[friend]	[friend]	[friend]	2.64% -85.4%	7.16% 171.6%	3.71% -48.1%	8.57% 130.8%	3.34% -61.0%	2.39% -28.4%	-2.62% -	-0.82% -	-0.5% -	0.08% -